Antibody-drug conjugates remain red-hot in 2026’s biopharma M&A splurge. The overall ADC category will be worth $57 billion by 2032, according to Evaluate Pharma.
Gilead’s $3 billion acquisition of Tubulis and Lilly’s of CrossBridge Bio are two of the latest deals. More will come as ADCs expand to hit new targets and carry new payloads.
We’ve just published a new report on the ADC space which you can find here. And for a few highlights, you can watch my summary in the video below.